




RealRate

PHARMACEUTICAL 2014

United Therapeutics Corp
Rank 77 of 234



The relative strengths and weaknesses of United Therapeutics Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of United Therapeutics Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 56% points. The greatest weakness of United Therapeutics Corp is the variable Liabilities, Current, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 309%, being 67% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	909,013
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	687,674
Liabilities, Non-Current	91,858
Other Assets	713,604
Other Compr. Net Income	1,774
Other Expenses	235,470
Other Liabilities	3,724
Other Net Income	-13,596
Other Revenues	1,116,984
Property and Equipment	464,950
Research and Development	299,348
Selling, General and Administrative Expense	394,010

Output Variable	Value in 1000 USD
Assets	2,087,567
Liabilities	783,256
Expenses	928,828
Revenues	1,116,984
Stockholders Equity	1,304,311
Net Income	174,560
Comprehensive Net Income	175,447
BaseVar	2,466,002
ECR before LimitedLiability	210%
Economic Capital Ratio	309%